You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK)年度純利達25.69億元 末期息6.51分
格隆匯 03-30 16:57

格隆匯3月30日丨翰森製藥(03692.HK)公佈,截至2020年12月31日止年度,公司收入86.9億元人民幣,同比增長0.1%;期間溢利25.69億元,同比增長0.5%;每股盈利0.44元,末期股息每股人民幣6.51分。

公司是中國製藥公司當中研發團隊規模最大的公司之一。公司的專責專業研發團隊由位於上海、連雲港和常州的三個開發中心的超過1,600名研究人員組成。公司擁有多個國家級研發稱號,包括國家級技術中心、博士後科研工作站及國家重點實驗室。

期間研發開支約人民幣12.5億元,同比增長約11.7%,佔收入比例約14.4%。新產品銷售佔集團收入約23.7%;2019年度,新產品銷售佔集團收入約6.1%。

2020年,儘管突如其來的新冠疫情影響了社會經濟發展,但中國有效的管控措施,使得社會經濟活動恢復正常,進入到疫情常態化的狀態。因疫情的影響,廣大民眾對於健康的意識反而進一步提高,中國巨大的醫療需求不斷提升。國家醫改持續深入推進,醫療保障制度、藥品管理制度和藥品一致性評價等方面新政策實施落地,為整個醫藥行業的發展帶來重大挑戰與機遇。

面對政策環境、市場環境的新變化以及疫情的影響,公司積極應對,堅定並加快創新發展的步伐,實現全面轉型升級。隨着阿美樂(甲磺酸阿美替尼片)、孚來美(聚乙二醇洛塞那肽注射液)、豪森昕福(甲磺酸氟馬替尼片)三個1類創新藥的獲批並納入醫保,公司的創新轉型已步入收穫期,公司的綜合競爭力進一步得到提升。公司相信,隨着不斷增強的創新能力,進一步豐富產品管線組合,維持高層次產品質量,保障穩定的生產供應,依託自身積累的出色的商業化能力,將推動公司持續、穩定、健康發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account